Clinical Trial Update: Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1/Phase 2 study of an HLA-A*0201-restricted peptide vaccine for gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• HLA-A*0201-restricted peptide vaccine therapy

Snippet

Sponsor: Tokyo University | Conditions: Gastric Cancer | Phase 1, Phase 2 | Status: COMPLETED